Cataract News and Research

Latest Cataract News and Research

TLC plans for Laser Eye Centers in Southern California from Los Angeles to San Diego

TLC Vision announced today plans for a continued presence in Southern California, from Los Angeles to San Diego. The renewed commitment includes an agreement to maintain the long-standing relationship with Drs. Alan M. Berg and Robert E. Feinfield, which forms The Berg-Feinfield/TLC Laser Eye Centers located throughout the Los Angeles area.

19 Feb 2011

Phase III RISE study of Lucentis for DME meets primary endpoint

Genentech, Inc., a member of the Roche Group, announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious complication of diabetes that affects up to 10 percent of people with the disease and can lead to blurred vision, severe vision loss and blindness.

14 Feb 2011

Alimera reports 36-month results from ILUVIEN Phase 3 FAME study for DME

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported results through month 36 of the completed FAME™ Study.

4 Feb 2011

Positive top-line results from ILUVIEN Phase 3 trial in patients with DME

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN for the treatment of Diabetic Macular Edema, today announced month 36, top-line readout results for the FAME Study prepared by its licensee, Alimera Sciences.

4 Feb 2011

Alcon fourth quarter sales raise 5.7% to $1.81 billion in 2010

Alcon, Inc. reported that global sales rose 5.7 percent to $1.81 billion for the fourth quarter of 2010. Revenue from acquisitions added 100 basis points to sales growth in the quarter, while foreign currency fluctuations reduced reported sales growth by 20 basis points.

27 Jan 2011

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2010.

27 Jan 2011

Interventions for preventing falls in older persons should include an exercise component

In the first update of the American Geriatrics Society and the British Geriatric Society's guidelines on preventing falls in older persons since 2001, they now recommend that all interventions for preventing falls should include an exercise component and that a number of new assessments should be used, including; feet and footwear, fear of falling, and ability to carry out daily living activities.

13 Jan 2011

Study supports use of PRX as an anti-cataract agent

Scientists are reporting a scientific basis for the long-standing belief that a widely used non-prescription drug in China and certain other countries can prevent and treat cataracts, a clouding of the lens of the eye that is a leading cause of vision loss worldwide. Their study appears in Inorganic Chemistry, an ACS journal.

13 Jan 2011

Surge in cataract surgeries fuels intraocular lens market to almost $1.4 billion

According to two new reports by iData Research, the leading global authority in medical device and pharmaceutical market research, growth in the use of optical coherence tomography (OCT) for the detection of ocular conditions will drive the U.S. diagnostic ophthalmic market to over $650 million by 2017.

12 Jan 2011

STAAR Surgical anticipates fourth quarter revenue to exceed $14.2 million

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that it expects revenue for the fourth quarter ended December 31, 2010 to exceed $14.2 million. Revenues for the full year were approximately $55 million, a 7% increase over 2009 revenues, driven by an increase of approximately 10% in revenues from the core ICL and IOL product lines.

11 Jan 2011

Insite Vision announces completion of patient enrollment in ISV-303 Phase 1/2 trial for post surgical ocular pain, inflammation

InSite Vision Incorporated, a company developing novel ophthalmic therapeutics, today announced that patient enrollment was recently completed in the company's Phase 1/2 clinical trial of ISV-303, a novel compound being developed to reduce the pain and inflammation associated with ocular surgery.

6 Jan 2011

EDMA to endorse the campaign on Hypoparathyroidism

On the occasion of the World Hypoparathyroidism Awareness Day 2011, EDMA, the European Diagnostic Manufacturers Association, highlights the crucial role the In Vitro Diagnostic (IVD) industry can play to effectively testing this rare endocrine condition.

5 Jan 2011

STAAR Surgical exceeds 200,000 Visian ICL global implants

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that the worldwide total number of Visian® ICL implants in patients has exceeded 200,000. Since 1994, STAAR's Implantable Collamer® Lenses (ICLs) have been used in refractive eye surgery as an alternative to LASIK. Manufactured with STAAR's proprietary Collamer material, Visian ICLs provide a safe and effective alternative in the permanent correction of myopia, hyperopia, and in the case of the Toric ICL, astigmatism.

4 Jan 2011

Britain’s NHS falls short in providing services

British patients are being denied routine procedures varying from hip replacements, to cataract removal and wisdom tooth extraction as trusts are cutting back on surgeries and diagnostic procedures to save money. There is also a restriction preventing patients undergoing procedures for lifestyle reasons and those considered “low priority”. This includes obesity surgeries, mild varicose veins, fertility treatments, back injections for pain, hip and knee replacement in obese patients etc.

20 Dec 2010

NextGen Healthcare announces partnership with Wills Eye for meaningful use

NextGen Healthcare Information Systems, a wholly owned subsidiary of Quality Systems, and leading provider of healthcare information systems and connectivity solutions, today announced an agreement with Wills Eye Health System to deploy NextGen® Ambulatory EHR and NextGen® Practice Management.

16 Dec 2010

ISTA commences bepotastine besilate nasal spray Phase 2 study in seasonal allergic rhinitis

ISTA Pharmaceuticals, Inc., today announced it has initiated a Phase 2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group environmental study will evaluate the safety and efficacy of bepotastine besilate, dosed twice daily, in patients presenting with allergic rhinitis caused by one of the most potent seasonal allergy triggers, Mountain Cedar pollen.

14 Dec 2010

Alliance of Specialty Medicine calls for new, permanent Medicare reimbursement formula

The Alliance of Specialty Medicine (Alliance) today called on Congress to permanently fix Medicare's Sustainable Growth Rate (SGR) after lawmakers once again passed a temporary fix, thereby postponing unprecedented reimbursement cuts to Medicare doctors until 2012.

10 Dec 2010

Calhoun Vision LAL Light Adjustable Lens for customized cataract surgery

Vision RejuvenationTM Victoria, a Canadian leader in advanced cataract and refractive lens exchange surgery has become the first centre in Canada to implant the world's first Light Adjustable Intraocular Lens.

7 Dec 2010

Alliance of Specialty Medicine calls for permanent fix to Medicare SGR formula

In response to Congress acting to postpone unprecedented reimbursement cuts to doctors who treat Medicare patients, The Alliance of Specialty Medicine (Alliance) today called on lawmakers to work towards a permanent solution to fix to the program's Sustainable Growth Rate (SGR) formula so temporary fixes would no longer be necessary.

1 Dec 2010